Merck drops early-stage TROP ADC, keeps deal doors open as Keytruda clock ticks

On the heels of several big buys, Merck still has eyes for M&A—particularly in the oncology, immunology and cardiometabolic spaces—as the quest continues for a candidate that can top Keytruda.